--- title: "Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26 | NUS Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/295576593.md" description: "Stonegate Capital Partners updated its coverage on NU Skin Enterprises (NUS), noting that Q2 2026 revenue of $320.1M missed estimates, while adjusted EPS matched at $0.20. Management lowered FY26 revenue guidance to $1.28B-$1.35B and adjusted EPS to $0.70-$0.90. The India launch was delayed to H1 2027. Stonegate views the revised outlook as reflecting a softer near-term setup, with Prysm iO adoption and cost actions remaining key drivers for 2027." datetime: "2026-08-11T12:24:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295576593.md) - [en](https://longbridge.com/en/news/295576593.md) - [zh-HK](https://longbridge.com/zh-HK/news/295576593.md) generator: "portal-rs" --- # Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26 | NUS Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google Dallas, Texas--(Newsfile Corp. - August 11, 2026) - NU Skin Enterprises Inc. (NYSE: NUS): Stonegate Capital Partners updates their coverage on NU Skin Enterprises Inc. (NYSE: NUS). NUS reported revenue, adj NI, and adj EPS of $320.1M, $10.0M, and $0.20, respectively. This compares to our estimates of $345.2M, $10.3M, and $0.20, respectively. GAAP EPS was $(5.14), primarily reflecting a $78.9M non-cash goodwill impairment, which was largely a GAAP accounting item, and a $167.5M deferred-tax valuation allowance, both excluded from adjusted results. Core Nu Skin gross margin improved 20 bps y/y to 77.7%, while consolidated gross margin declined 60 bps to 68.2% and adjusted operating margin fell 190 bps to 6.1%. Nu Skin and Rhyz revenue declined 15.5% and 25.0% y/y, respectively. Management reduced FY26 revenue guidance to $1.28B-$1.35B from $1.35B $1.50B and adjusted EPS to $0.70-$0.90 from $0.80-$1.20. India also moved to 1H27 from year-end 2026 as NUS refines local sourcing, logistics, technology integration, and the affiliate model. We believe the revised outlook reflects a lower near-term setup, with Prysm iO adoption, sales-force productivity, and cost actions remaining the primary 2027 drivers. To view the full announcement, including downloadable images, bios, and more, click here. **Key Takeaways:** - Revenue was $320.1M in 2Q26, while adj. EPS of $0.20 matched our estimate despite a weaker top line, with Core Nu Skin gross margin improving 20 bps y/y to 77.7%. Management lowered FY26 revenue guidance to $1.28B-$1.35B and adjusted EPS guidance to $0.70-$0.90, reinforcing a softer near-term setup but leaving margin improvement and cost optimization as important levers into 2027. - Prysm iO remains the central longer-term growth initiative, with more than 39,000 devices placed and 2.5M scans completed as NUS targets 50,000-60,000 devices by year-end. We increasingly view the platform as a sales-force productivity tool, with AI-enabled assessments, recommendations, and 90-day wellness plans expected to help leaders deepen customer engagement, improve conversion, and broaden monetization across beauty and wellness. - Sales-force trends showed early signs of stabilization, with sales leaders down 9% y/y versus a 13% decline in 1Q and essentially flat q/q, while Mainland China sales leaders increased 2% y/y. Although recruiting remains below levels required for sustainable growth and India has shifted to 1H27, Prysm iO training, compensation changes, leadership development initiatives, and the East-West operating model provide several potential drivers for improved productivity and profitability next year. *Click image above to view full announcement.* * * * **About Stonegate** Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. **Contacts:** Stonegate Capital Partners (214) 987-4121 info@stonegateinc.com Source: Stonegate, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309257 ### Related Stocks - [NUS.US](https://longbridge.com/en/quote/NUS.US.md) ## Related News & Research - [Nu Skin Ranked the World’s #1 Company for Beauty and Wellness Device Systems for Third Consecutive Year | NUS Stock News](https://longbridge.com/en/news/297932856.md) - [It's 2026 and Gurus Are Still Promising $10K a Month From Low-Effort AI Side Hustles. It Feels Like 99% of the Money Is ‘About Selling the Shovel’](https://longbridge.com/en/news/298728697.md) - [Ton Strategy Chief Accounting Officer Bill John Rivard disposes of USD 41,254 common shares](https://longbridge.com/en/news/298359100.md) - [Graham Holdings Company Declares Regular Quarterly Dividend | GHC Stock News](https://longbridge.com/en/news/298616719.md) - [Avid, Google Cloud expand partnership to roll out browser-based Media Composer with Gemini integration](https://longbridge.com/en/news/298698393.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**